At the ObesityWeek 2024, AstraZeneca Plc (NASDAQ:AZN) shared data abstracts highlighting early data from AZD5004/ECC5004. In ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is ...

One of those trials of the drug, called AZD5004, will focus on reduction in body weight on average in obese and overweight ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial.

Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price ...

Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...

Effectiveness and safety data from Viking’s study, released Sunday at an industry conference, show that an obesity pill could ...